Key result
TAVI benefits inoperable patients but elevated stroke and periprosthetic leak risks warrant caution in lower-risk candidates.
Why the study?
The expanding use of TAVI in high-risk and inoperable patients with aortic valve disease raises concerns about its safety and efficacy compared to conventional AVR in lower-risk patients.
Does transcatheter aortic valve implantation (TAVI) improve outcomes compared to conventional aortic valve replacement in patients with aortic valve disease?
Does transcatheter aortic valve implantation (TAVI) improve outcomes compared to conventional aortic valve replacement in patients with aortic valve disease?
TAVI is effective for inoperable patients, but its complication profile suggests caution before expanding its use to patients at low risk for conventional AVR.
TAVI expansion in high-risk elderly leaves open durability and generalizability; prospective data needed before wider adoption.
Conventional aortic valve replacement (AVR) surgery has been in clinical use since 1960. Results, particularly in high-risk populations such as the very elderly and frail, continue to improve in response to the challenges posed by this growing segment of the patient population. Transcatheter aortic valve implantation (TAVI) is a fairly recent development, performed for the first time in 2002. The last decade has seen an exponential growth in the application of this technology in higher-risk populations. Results of recent randomized prospective trials demonstrate both the future promise and current problems of the TAVI approach. Many patients deemed inoperable for AVR have been treated successfully by TAVI. However, elevated procedural and late mortality rates, excessive early and late stroke, and a significant incidence of periprosthetic aortic valve insufficiency and patient-prosthesis mismatch all suggest caution in extending this technology to patients able to undergo conventional AVR with a low risk of early or late complications.
No takes yet. Share an insight, caveat, or question.
Gerald M. Lawrie (2012) conducted a review in Aortic Valve Disease. Transcatheter Aortic Valve Implantation (TAVI) vs. Conventional Aortic Valve Replacement (AVR) was evaluated. Transcatheter aortic valve implantation (TAVI) is effective for inoperable patients with severe aortic stenosis, but elevated risks of stroke and periprosthetic insufficiency suggest caution in extending its use to lower-risk surgical candidates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: